If you experience any suspected side effects whilst participating in a retatrutide trial or after stopping treatment, these should be reported to the trial team and, where appropriate, via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which enables reporting of suspected adverse reactions to medicines and vaccines in the UK
having a metallic taste in the mouth whenever they eat
Tirzepatide is given as a subcutaneous injection, meaning it is injected into the fatty tissue just under the skin
Check your email to confirm your early access and lock in 20% off your first peptide order when the service launches
Reference Mozaffarian, D., Agarwal, M., Aggarwal, M., et al